[1] US FDA. The draft concept paper on drug-diagnostic co-development[S]. The US Food and Drug Administration: Rockville, MD, 2005. [2] Liu JP, Lin JR. Statistical methods for targeted clinical trials under enrichment design[S]. J Formos Med Assoc, 2008, 107(12):S35-S42. [3] Liu JP, Lin JR. Inference on treatment effects for targeted clinical trials under enrichment design[J]. Pharm Stat, 2009, 8(4):356-370. [4] Gerlach H, Toussaint S. Sensitive, specific, predictive…statistical basics: How to use biomarkers[J]. Crit Care Clin, 2011, 27(2):215-227. [5] Liu JP. Targeted clinical trials. In: Chow SC, Cosmatos JT, et al. Translational Medicine: Strategies and Statistics Methods[M]. New York: Taylor & Francis, 2008:87-111. [6] Liu JP, Chow SC. Issues on the diagnostic multivariate index assay and targeted clinical trials[J]. J Biopharm Stat,2008, 18(1):167-182. [7] Ray P, Le Manach Y, Riou B. Statistical Evaluation of a Biomarker[J]. Anesthesiology, 2010, 112(4):1023-1040. [8] Dempster AP, Laird NM, Rubin DB. Maximum likelihood estimation from incomplete data via the EM algorithm (with discussion)[J].J R Stat Soc Series B Stat Methodol,1977, 39(1):1-38. [9] McLachlan GJ, Krishnan T. The EM algorithm and extensions[M]. Wiley: New York, 1997:40-80. [10] Efron B. Bootstrap: Another look at Jackknife[J]. Ann Statist, 1979, 7(1):1-26. [11] Efron B, Tibshirani RJ. An Introduction to the Bootstrap[M]. New York: Chapman & Hall, 1993:39-82. |